ALPHARX INC

hier noch was gehen?!?! 

Riso Pharma http://research.scottrade.com/public/markets/news/news.asp?section=headlines&docKey=100-278x9827-1

MARKHAM, ON, Sept. 14 /PRNewswire-FirstCall/ -- AlphaRx Inc. (OTC BB: ALRX). Speaking at the 11th Annual Rodman Renshaw Healthcare Conference in New York City, AlphaRx Director Dr. David Milroy presented a company overview focusing on the Company's product pipeline, nano drug delivery platform and the significant developments anticipated within the next 12 months. In Summary, AlphaRx will have 3-4 products in different stages of clinical development by the end of 2010, which have major market indications and opportunities, producing a portfolio of short to long term drug candidates to position the company for stable and sustainable growth. In addition, AlphaRx presented 2 new product candidates ARX1088 and ARX2038 which are being developed for herpes and lipid management respectively. These products have excellent safety profile and have over 25 years of successful clinical applications outside the US. AlphaRx is developing a new dosage form for ARX1088 and ARX2038 and planning to initiate Phase II clinical trails in the later part of 2010. http://www.finanznachrichten.de/nachrichten-2009-09/14940033-alpharx-presents-company-overview-and-new-product-candidates-at-the-rodman-renshaw-healthcare-conference-008.htm